Proceedings of the third international molecular pathological epidemiology (MPE) meeting

Cancer Causes and Control

Volumn 28, Issue 2, 2017, Pages 167-176

  Campbell, Peter T ^a   Rebbeck, Timothy R ^b,c   Nishihara, Reiko ^b,c   Beck, Andrew H ^d   Begg, Colin B ^e   Bogdanov, Alexei A ^f   Cao, Yin ^b,g   Coleman, Helen G ^h   Freeman, Gordon J ^c   Heng, Yujing J ^d   Huttenhower, Curtis ^b,i   Irizarry, Rafael A ^b,j   Kip, N Sertac ^k   Michor, Franziska ^b,j   Nevo, Daniel ^b   Peters, Ulrike ^l,m   Phipps, Amanda I ^l,m   Poole, Elizabeth M ^b,n   Qian, Zhi Rong ^c   Quackenbush, John ^b,j   Robins, Harlan ^l   Rogan, Peter K ^o   Slattery, Martha L ^p   Smith Warner, Stephanie A ^b   Song, Mingyang ^b,g   VanderWeele, Tyler J ^b   Xia, Daniel ⁿ   Zabor, Emily C ^e   Zhang, Xuehong ⁿ   Wang, Molin ^b   Ogino, Shuji ^b,c,j,n   more..

^a AMERICAN CANCER SOCIETY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

ⁱ BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k GEISINGER HEALTH SYSTEM   (United States)

^l USA   (United States)

^m UNIVERSITY OF WASHINGTON   (United States)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o UNIVERSITY OF WESTERN ONTARIO   (Canada)

^p UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Meeting report; Molecular pathological epidemiology; Proceedings

Indexed keywords

BIOINFORMATICS; BIOSTATISTICS; BREAST CANCER; CANCER IMMUNOLOGY; CLINICAL MEDICINE; COLORECTAL CANCER; HUMAN; LIFESTYLE; LUNG CANCER; MOLECULAR EPIDEMIOLOGY; MOLECULAR IMAGING; MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; PROGNOSIS; REVIEW; STATISTICAL ANALYSIS; EPIDEMIOLOGY; MASSACHUSETTS; MOLECULAR PATHOLOGY; NEOPLASM;

BOSTON; EPIDEMIOLOGY; HUMANS; NEOPLASMS; PATHOLOGY, MOLECULAR;

EID: 85009728712     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-016-0845-z     Document Type: Review

References (68)

1. Ogino S, Stampfer M (2010) Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 102:365–367
2. Ogino S, Lochhead P, Chan AT et al (2013) Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 26:465–484
3. Nishi A, Kawachi I, Koenen KC, Wu K, Nishihara R, Ogino S (2015) Lifecourse epidemiology and molecular pathological epidemiology. Am J Prev Med 48:116–119
4. Nishi A, Milner DA Jr, Giovannucci EL et al (2016) Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn 16:11–23
5. Ogino S, Chan AT, Fuchs CS, Giovannucci E (2011) Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60:397–411
6. Ogino S, Nishihara R, VanderWeele TJ et al (2016) Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology 27:602–611
7. Curtin K, Slattery ML, Samowitz WS. (2011) CpG island methylation in colorectal cancer: past, present and future. Pathol Res Int, pp 902674.
8. Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R (2014) Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol 20:6055–6072
9. Jiang MJ, Dai JJ, Gu DN, Huang Q, Tian L (2016) Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochim Biophys Acta 1866:163–176
10. Kuipers EJ, Grady WM, Lieberman D, et al. (2015) Colorectal cancer. Nat Rev Dis Primers. 1:15065.
11. Martinez-Useros J, Garcia-Foncillas J (2016) Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med 14:21
12. Kuroiwa-Trzmielina J, Wang F, Rapkins RW et al (2016) SNP rs16906252C>T is an expression and methylation quantitative trait locus associated with an increased risk of developing MGMT-methylated colorectal cancer. Clin Cancer Res 22:6266–6277
13. Chia WK, Ali R, Toh HC (2012) Aspirin as adjuvant therapy for colorectal cancer–reinterpreting paradigms. Nat Rev Clin Oncol 9:561–570
14. Hughes LA, Khalid-de Bakker CA, Smits KM, et al. (2012) The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta. 1825: 77–85.
15. Buchanan DD, Win AK, Walsh MD et al (2013) Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases. Cancer Epidemiol Biomarkers Prev 22:917–926
16. Figueiredo JC, Lewinger JP, Song C et al (2011) Genotype-environment interactions in microsatellite stable/microsatellite instability-low colorectal cancer: results from a genome-wide association study. Cancer Epidemiol Biomark Prev 20:758–766
17. Lee PN, Forey BA, Coombs KJ (2012) Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer 12:385
18. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P (2008) Smoking and colorectal cancer: a meta-analysis. JAMA 300:2765–2778
19. Secretan B, Straif K, Baan R et al (2009) A review of human carcinogens–Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 10:1033–1034
20. Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50:113–130
21. Poynter JN, Haile RW, Siegmund KD et al (2009) Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomark Prev 18:2745–2750
22. Slattery ML, Curtin K, Anderson K et al (2000) Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 92:1831–1836
23. Limsui D, Vierkant RA, Tillmans LS et al (2010) Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 102:1012–1022
24. Nishihara R, Morikawa T, Kuchiba A et al (2013) A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol 178:84–100
25. Ogino S, Campbell PT, Nishihara R et al (2015) Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control 26:959–972
26. Curtin K, Samowitz WS, Ulrich CM et al (2011) Nutrients in folate-mediated, one-carbon metabolism and the risk of rectal tumors in men and women. Nutr Cancer 63:357–366
27. The Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337
28. Giannakis M, Hodis E, Jasmine Mu X et al (2014) RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet 46:1264–1266
29. Giannakis M, Mu XJ, Shukla SA et al (2016) Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 15:857–865
30. Howie B, Sherwood AM, Berkebile AD et al (2015) High-throughput pairing of T cell receptor alpha and beta sequences. Sci Transl Med 7:301ra131
31. Masugi Y, Nishihara R, Yang J et al (2016) Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut (in press)
32. Mima K, Nishihara R, Nowak JA et al (2016) MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer. Immunol Res 4:33–40
33. Mima K, Sukawa Y, Nishihara R et al (2015) Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol 1:653–661
34. Ogino S, Galon J, Fuchs CS, Dranoff G (2011) Cancer immunology–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 8:711–719
35. Song M, Nishihara R, Wang M et al (2016) Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut 65:296–304
36. Hanyuda A, Ogino S, Qian ZR et al (2016) Body mass index and risk of colorectal cancer according to tumor lymphocytic infiltrate. Int J Cancer 139:854–868
37. Song M, Nishihara R, Cao Y et al (2016) Marine omega-3 polyunsaturated fatty acid intake and risk of colorectal cancer characterized by tumor-infiltrating T cells. JAMA Oncol 2:1197–1206
38. Tan DS, Mok TS, Rebbeck TR (2016) Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. J Clin Oncol 34:91–101
39. Almendro V, Cheng YK, Randles A, et al. (2014) Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep 6:514–527.
40. Almendro V, Kim HJ, Cheng YK et al (2014) Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 74:1338–1348
41. Janiszewska M, Liu L, Almendro V et al (2015) In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet 47:1212–1219
42. Bogdanov AA Jr, Dixon AJ, Gupta S et al (2016) Synthesis and testing of modular dual-modality nanoparticles for magnetic resonance and multispectral photoacoustic imaging. Bioconjug Chem 27:383–390
43. Begg CB, Orlow I, Zabor EC, et al. (2015) Identifying etiologically distinct sub-types of cancer: a demonstration project involving breast cancer. Cancer Med 4:1432–1439.
44. VanderWeele TJ, Robins JM (2007) The identification of synergism in the sufficient-component-cause framework. Epidemiology 18:329–339
45. VanderWeele TJ (2009) Sufficient cause interactions and statistical interactions. Epidemiology 20:6–13
46. Vanderweele TJ (2010) Sufficient cause interactions for categorical and ordinal exposures with three levels. Biometrika 97:647–659
47. Glass K, Quackenbush J, Spentzos D, Haibe-Kains B, Yuan GC (2015) A network model for angiogenesis in ovarian cancer. BMC Bioinform 16:115
48. Jaffe AE, Irizarry RA (2014) Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol 15:R31
49. Huttenhower C, Knight R, Brown CT et al (2014) Advancing the microbiome research community. Cell 159:227–230
50. Dubin N, Pasternack BS (1986) Risk assessment for case-control subgroups by polychotomous logistic regression. Am J Epidemiol 123:1101–1117
51. Begg CB, Zabor EC, Bernstein JL, Bernstein L, Press MF, Seshan VE (2013) A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med 32:5039–5052
52. Chatterjee N, Sinha S, Diver WR, Feigelson HS (2010) Analysis of cohort studies with multivariate and partially observed disease classification data. Biometrika 97:683–698
53. Wang M, Kuchiba A, Ogino S (2015) A meta-regression method for studying etiological heterogeneity across disease subtypes classified by multiple biomarkers. Am J Epidemiol 182:263–270
54. Rosner B, Glynn RJ, Tamimi RM et al (2013) Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol 178:296–308
55. Schildkraut JM, Iversen ES, Akushevich L et al (2013) Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors. Cancer Epidemiol Biomark Prev 22:1709–1721
56. Nevo D, Zucker DM, Tamimi RM, Wang M (2016) Accounting for measurement error in biomarker data and misclassification of subtypes in the analysis of tumor data. Stat Med 35:5686–5700
57. Wang M, Spiegelman D, Kuchiba A et al (2016) Statistical methods for studying disease subtype heterogeneity. Stat Med 35:782–800
58. The Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70
59. Dorman SN, Baranova K, Knoll JH et al (2016) Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning. Mol Oncol 10:85–100
60. Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302:649–658
61. Reimers MS, Bastiaannet E, Langley RE, et al. (2014) Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med 174:732–739.
62. Domingo E, Church DN, Sieber O et al (2013) Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 31:4297–4305
63. Cao Y, Nishihara R, Qian ZR et al (2016) Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes. Gastroenterology 151:879–892
64. Campbell PT, Deka A, Briggs P et al (2014) Establishment of the cancer prevention study II nutrition cohort colorectal tissue repository. Cancer Epidemiol Biomark Prev 23:2694–2702
65. Campbell PT, Jacobs ET, Ulrich CM et al (2010) Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst 102:391–400
66. Campbell PT, Newton CC, Newcomb PA et al (2015) Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomark Prev 24:1229–1238
67. Newcomb PA, Baron J, Cotterchio M et al (2007) Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomark Prev 16:2331–2343
68. Phipps AI, Ahnen DJ, Campbell PT et al (2014) Family history of colorectal cancer is not associated with colorectal cancer survival regardless of microsatellite instability status. Cancer Epidemiol Biomark Prev 23:1700–1704